Holen Sie sich die Stockscreener-App
123.84
0.18%
0.22
Handel nachbörslich:
123.52
-0.32
-0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$123.62
Offen:
$123.71
24-Stunden-Volumen:
5.83M
Relative Volume:
1.01
Marktkapitalisierung:
$215.54B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.90B
KGV:
15.53
EPS:
7.9725
Netto-Cashflow:
$6.92B
1W Leistung:
-2.63%
1M Leistung:
-7.99%
6M Leistung:
-6.76%
1J Leistung:
+4.42%
1-Tages-Spanne:
$122.44
$124.06
1-Wochen-Bereich:
$122.44
$128.45
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
123.84 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.16 | 136.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.20 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.07 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories (NYSE:ABT) Is Favoured by Institutional Owners Who Hold 80% of the Company - 富途牛牛
Abbott Laboratories $ABT Shares Bought by State of Michigan Retirement System - MarketBeat
My Favorite Dividend King to Buy in November - The Motley Fool
SS&H Financial Advisors Inc. Grows Stake in Abbott Laboratories $ABT - MarketBeat
Tredje AP fonden Has $109.24 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Holdings Lifted by Tsfg LLC - MarketBeat
iA Global Asset Management Inc. Reduces Position in Abbott Laboratories $ABT - MarketBeat
AlphaStar Capital Management LLC Buys Shares of 2,245 Abbott Laboratories $ABT - MarketBeat
Greater Midwest Financial Group LLC Buys 18,927 Shares of Abbott Laboratories $ABT - MarketBeat
Syverson Strege & Co Acquires 2,723 Shares of Abbott Laboratories $ABT - MarketBeat
Integrity Alliance LLC. Reduces Position in Abbott Laboratories $ABT - MarketBeat
Assetmark Inc. Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Spire Wealth Management - MarketBeat
Abbott Laboratories $ABT Shares Sold by Fisher Funds Management LTD - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Linscomb Wealth Inc. - MarketBeat
How Abbott Laboratories stock reacts to inflationary pressuresMarket Trend Review & Free Technical Confirmation Trade Alerts - newser.com
Technical signs of recovery in Abbott LaboratoriesWatch List & Trade Opportunity Analysis - newser.com
Is Abbott Laboratories a candidate for recovery playEarnings Performance Report & Weekly Sector Rotation Insights - newser.com
Looking at the Narrative for Abbott as Legal Wins and Device Growth Shift the Outlook - Yahoo Finance
Simon Quick Advisors LLC Buys 4,430 Shares of Abbott Laboratories $ABT - MarketBeat
Strs Ohio Raises Stake in Abbott Laboratories $ABT - MarketBeat
Amalgamated Bank Purchases 21,362 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Atria Investments Inc - MarketBeat
Abbott Laboratories $ABT Shares Sold by Keybank National Association OH - MarketBeat
Hantz Financial Services Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
World Investment Advisors Boosts Holdings in Abbott Laboratories $ABT - MarketBeat
Will a bounce in Abbott Laboratories offer an exitJuly 2025 Fed Impact & AI Based Buy and Sell Signals - newser.com
Is a relief rally coming for Abbott Laboratories holdersEarnings Risk Report & Free Community Supported Trade Ideas - newser.com
What is the fair value estimate for Abbott Laboratories (ABL) stock in 2025 - newser.com
Daymark Wealth Partners LLC Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Zacks Analyst Blog Highlights International Business Machines, Micron and Abbott - sharewise.com
Analyst IMS Investment Management Services Ltd. Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Whalen Wealth Management Inc. Purchases New Position in Abbott Laboratories $ABT - MarketBeat
Jennison Associates LLC Grows Stock Position in Abbott Laboratories $ABT - MarketBeat
Will earnings trigger a reversal in Abbott Laboratories2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Patient sues Abbott after early heart valve replacement - Cardiovascular Business
Top Stock Reports for IBM, Micron & Abbott - Yahoo Finance
Abbott Trifecta Heart Valve Lawsuit Filed Over Device Failure, Removal - AboutLawsuits.com
New York Life Investment Management LLC Acquires 4,494 Shares of Abbott Laboratories $ABT - MarketBeat
Fairfield Financial Advisors LTD Sells 2,587 Shares of Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a buy in volatile markets2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - newser.com
Mizuho Markets Americas LLC Sells 8,006 Shares of Abbott Laboratories $ABT - MarketBeat
Biltmore Family Office LLC Has $3.97 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Howard Capital Management Inc. - MarketBeat
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $162 - 富途牛牛
Transcend Capital Advisors LLC Sells 3,073 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback - simplywall.st
Data supports Abbott Tendyne mitral valve replacement - MassDevice
First National Trust Co Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a good choice for value investors2025 Geopolitical Influence & AI Forecasted Stock Moves - fcp.pa.gov.br
What makes Abbott Laboratories stock attractive to growth fundsM&A Rumor & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.11%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):